Abstracts tagged "Polychondritis"

Abstract Number: 051 • 2023 Pediatric Rheumatology Symposium
Juvenile Relapsing Polychondritis: A Single Center Cohort
Angela Chun¹, Sarah Molina¹, Marietta De Guzman² and Maria Pereira Palacios¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Relapsing polychondritis (RPC) is a rare multisystemic autoimmune disease associated with recurrent, progressive inflammation in cartilaginous structures. In children, the most common manifestations are…
Abstract Number: 905 • 2019 ACR/ARP Annual Meeting
A Third of Relapsing Polychondritis Patients with Ear Involvement at Presentation Had Airway Involvement at the Last Follow-up with a High Mortality Rate
Jun Shimizu¹, Yoshihisa Yamano ¹, Kimito Kawahata ² and Noboru Suzuki ¹, ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: We have reported that 239 patients with relapsing polychondritis (RP) were divided into three subgroups, namely patients with airway involvement (A subgroup, 20% of…
Abstract Number: 1316 • 2018 ACR/ARHP Annual Meeting
Respiratory Involvement in Relapsing Polychondritis – a Single Centre Study
Catherine D Hughes¹, Begona Lopez Garcia¹, CheeKen Cheah¹, Yih Jia Poh², Shirish Sangle¹ and David D'Cruz³, ¹Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, Singapore, ³Louise Coote Lupus Unit, Guy's and St. Thomas' Hospital, London, United Kingdom
Background/Purpose: Relapsing Polychondritis (RP) is a rare immune mediated inflammatory disorder that may result in destruction of cartilaginous tissues. Diagnostic delay is common due to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].